X0206 3 2020-12-11 0 0001703057 AbCellera Biologics Inc. ABCL 0001352908 Hayden Michael R C/O ABCELLERA BIOLOGICS INC. 2215 YUKON STREET VANCOUVER A1 V5Y 0A1 BRITISH COLUMBIA, CANADA 1 0 0 0 Common Shares 985750 I See Footnote Common Shares 44580 I By spouse Stock Option (right to buy) 0.33 2029-09-11 Common Shares 540000 I See footnote Stock Option (right to buy) 2.76 2030-11-18 Common Shares 100000 D Convertible Note 17.00 Common Shares 117647 I See footnote These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest, if any, therein. 50% of the shares subject to such option vest and become exercisable on September 11, 2021 and 50% of the shares subject to such option vest and become exercisable on September 11, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date. The exercise price reported above was converted from the Canadian exercise price of CAD $0.43 using an exchange rate of CAD $1.27840 = US $1.00. 100% of the shares subject to such option vest and become exercisable on the date of the 2021 annual general meeting of the Issuer, subject to the Reporting Person's continuous service to the Issuer on such date. The exercise price reported above was converted from the Canadian exercise price of CAD $3.52 using an exchange rate of CAD $1.27840 = US $1.00. The convertible promissory note ("Convertible Note") has a maturity date of October 30, 2025 and the principal amount of the Convertible Note will convert upon the closing of the IPO into Common Shares at a conversion price equal to $17.00 per Common Share. Exhibit 24 - Power of Attorney /s/ Tryn Stimart, attorney-in-fact 2020-12-11